Modern imaging techniques in patients with multiple myeloma;Moderne Bildgebungsverfahren beim MultiplenMyelom

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 185, Issue 1, 2013, Pages 26-33

  Bannas, P ^a   Kroger N ^a   Adam, G ^a   Derlin, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

bone marrow infiltration; diagnostic radiology; hematologic diseases; multiple myeloma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; DIAGNOSTIC IMAGING; METHODOLOGY; REVIEW;

DIAGNOSTIC IMAGING; HUMANS; MULTIPLE MYELOMA;

EID: 84871716035     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0032-1325405     Document Type: Article

References (50)

1. Bataille R., Harousseau J. L. Multiple myeloma. N Engl J Med: 1997; 336 1657 1664
2. Buchbender C., Antoch G., Nawatny J. Meningeal plasmacytoma: delayed diagnosis with sequelae. Fortschr Röntgenstr: 2011; 183 761 762
3. Wu P., Davies F. E., Boyd K. et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma: 2009; 50 230 235
4. Varettoni M., Corso A., Pica G. et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol: 2010; 21 325 330
5. Brandmaier P., Kahn T., Stumpp P. Extraosseous myeloma manifestation of the thyroid cartilage. Fortschr Röntgenstr: 2011; 183 477 478
6. Dimopoulos M., Kyle R., Fermand J. P. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood: 2011; 117 4701 4705
7. Giralt S., Stadtmauer E. A., Harousseau J. L. et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia: 2009; 23 1904 1912
8. Shimoni A., Hardan I., Ayuk F. et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer: 2010; 116 3621 3630
9. Kroger N. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia: 2007; 21 1851 1858 (Pubitemid 47299957)
10. Barlogie B., Tricot G. J., van Rhee F. et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol: 2006; 135 158 164 (Pubitemid 44401612)
11. Blade J., Dimopoulos M., Rosinol L. et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol: 2010; 28 690 697
12. Kyle R. A., Durie B. G., Rajkumar S. V. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia: 2010; 24 1121 1127
13. Kyle R. A., Therneau T. M., Rajkumar S. V. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med: 2002; 346 564 569 (Pubitemid 34438817)
14. Dimopoulos M., Terpos E., Comenzo R. L. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia: 2009; 23 1545 1556
15. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer: 1975; 36 842 854
16. Durie B. G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer: 2006; 42 1539 1543 (Pubitemid 44137426)
17. Giuliani N., Rizzoli V., Roodman G. D. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood: 2006; 108 3992 3996 (Pubitemid 44913267)
18. Kyle R. A., Rajkumar S. V. Multiple myeloma. N Engl J Med: 2004; 351 1860 1873
19. Collins C. D. Multiple myeloma. Cancer Imaging: 2010; 10 20 31
20. Kyle R. A., Rajkumar S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia: 2009; 23 3 9
21. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol: 2003; 121 749 757
22. Edelstyn G. A., Gillespie P. J., Grebbell F. S. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol: 1967; 18 158 162
23. Wahlin A., Holm J., Osterman G. et al. Evaluation of serial bone X-ray examination in multiple myeloma. Acta Med Scand: 1982; 212 385 387 (Pubitemid 13221667)
24. Kropil P., Fenk R., Fritz L. B. et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol: 2008; 18 51 58 (Pubitemid 351217276)
25. Gleeson T. G., Moriarty J., Shortt C. P. et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol: 2009; 38 225 236
26. Lutje S., de Rooy J. W., Croockewit S. et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol: 2009; 88 1161 1168
27. Horger M., Kanz L., Denecke B. et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer: 2007; 109 1617 1626 (Pubitemid 46595698)
28. Horger M., Claussen C. D., Bross-Bach U. et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol: 2005; 54 289 297 (Pubitemid 40523623)
29. Chassang M., Grimaud A., Cucchi J. M. et al. Can low-dose computed tomographic scan of the spine replace conventional radiography? An evaluation based on imaging myelomas, bone metastases, and fractures from osteoporosis. Clin Imaging: 2007; 31 225 227 (Pubitemid 46964838)
30. Walker R., Barlogie B., Haessler J. et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol: 2007; 25 1121 1128 (Pubitemid 46596765)
31. Baur-Melnyk A., Buhmann S., Becker C. et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol: 2008; 190 1097 1104 (Pubitemid 351571514)
32. Baur-Melnyk A., Buhmann S., Durr H. R. et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol: 2005; 55 56 63 (Pubitemid 40798488)
33. Moulopoulos L. A., Dimopoulos M. A., Alexanian R. et al. Multiple myeloma: MR patterns of response to treatment. Radiology: 1994; 193 441 446 (Pubitemid 24338331)
34. Moulopoulos L. A., Gika D., Anagnostopoulos A. et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol: 2005; 16 1824 1828 (Pubitemid 41631247)
35. Moulopoulos L. A., Dimopoulos M. A., Smith T. L. et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol: 1995; 13 251 256
36. Hillengass J., Fechtner K., Weber M. A. et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol: 2010; 28 1606 1610
37. Moulopoulos L. A., Dimopoulos M. A., Weber D. et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol: 1993; 11 1311 1315 (Pubitemid 23199135)
38. Hillengass J., Bauerle T., Bartl R. et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol: 2011; 153 721 728
39. 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging: 2006; 33 525 531
40. 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica: 2007; 92 50 55 (Pubitemid 46232657)
41. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med: 2008; 49 195 200 (Pubitemid 351225656)
42. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo: 2008; 22 513 517
43. 18)F-FDG PET identifies high-risk myeloma. J Nucl Med: 2002; 43 1457 1463 (Pubitemid 35285870)
44. Brenner W., Friedrich R. E., Gawad K. A. et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging: 2006; 33 428 432
45. 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood: 2011; 118 5989 5995
46. 18)F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging
47. 18- fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood: 2009; 114 2068 2076
48. Callander N. S., Roodman G. D. Myeloma bone disease. Semin Hematol: 2001; 38 276 285 (Pubitemid 32717665)
49. 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging: 2012; 39 493 500
50. Bannas P., Hentschel H. B., Bley T. A. et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol: 2012; 22 2007 2012